The Mesothelioma Guide Blog

The U.S. Food and Drug Administration (FDA) granted ONCOFID‑P “orphan drug status” for treating malignant mesothelioma. ONCOFID‑P is a combination of paclitaxel and...

Treatment for peritoneal mesothelioma is today where treatment was three years ago for pleural mesothelioma. Tumor treating fields are not yet acceptable for non-surgical cases....

One of the toughest parts of fighting mesothelioma is detecting the rare cancer. Most people don’t know they have it until the tumors have progressed into organ cavities. Early...

Researchers at Memorial Sloan Kettering Cancer Center hope they can discover the safest dose for mesothelin‑targeted CAR T‑cell therapy. This is the next step in ongoing...

There are various types of immunotherapy. Could pairing two of them work for malignant mesothelioma? A new study out of the National Cancer Institute is combining an immune...

The next chapter in the Johnson & Johnson asbestos saga is almost written. It might be defined by one word: bankruptcy. According to reports from the Wall Street Journal and...

Update: 07/14/2021: The annual follow-up of this study provided new data on atezolizumab and bevacizumab for peritoneal mesothelioma. Most clinical trials experimenting with novel...

Mesothelioma can be quite a selective cancer. The only known cause is exposure to asbestos, which occurs in specific jobs at higher frequencies than other occupations. A common...

Immunotherapy and radiation therapy may have a synergistic effect on one another. For people with malignant mesothelioma, this is a source of hope. Two new clinical trials are...